Lupus (SLE) trials in China

In China 163 Also abroad 354

163 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
Where
Beijing
Age
18 years to 60 years
People
27
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06822881
Phase 1/2Taking people
A Study of GR1803 in Systemic Lupus Erythematosus
Where
Wuhan
Age
18 years to 60 years
People
44
Run by
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07348055
Phase 1Taking people
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Where
Bengbu
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762
Phase 1/2Taking people
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Where
Beijing
Age
6 years to 65 years
People
45
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06947473
Phase 1Taking people
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Where
Xuzhou
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801
Phase 1Taking people
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Where
Beijing, Hefei, Wuhan
Age
18 years to 65 years
People
18
Run by
Hangzhou Qihan Biotech Co., Ltd.
See details and how to joinNCT07444307
Phase 1Not yet taking people in China
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Where
Shanghai
Age
5 years to 18 years
People
12
Run by
Children's Hospital of Fudan University
See details and how to joinNCT07439029
Early phase 1Taking people
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
60
Run by
Changhai Hospital
See details and how to joinNCT07246096
Phase 1Taking people
Study of CD19 CAR-T Therapy for Refractory SLE
Where
Chongqing
Age
5 years and over
People
18
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07403097
Phase 2Not yet taking people in China
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
Where
Beijing
Age
18 years to 75 years
People
60
Run by
Simcere Pharmaceutical Co., Ltd
See details and how to joinNCT07393451
Phase 1/2Taking people
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
Where
Beijing
Age
18 years to 75 years
People
189
Run by
Excyte Biopharma Ltd
See details and how to joinNCT07010835
Phase 1Taking people
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
Where
Nanjing
Age
18 years and over
People
18
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07318259
No phaseNot yet taking people in China
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
Where
Jinan
Age
18 years to 65 years
People
180
Run by
Yipeng Liu
See details and how to joinNCT07069972
Phase 1Taking people
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
Where
Bengbu, Changsha, Guangzhou, Nanchang, Xuzhou
Age
18 years to 70 years
People
38
Run by
Nanjing Legend Biotech Co.
See details and how to joinNCT07331272
Phase 1Not yet taking people in China
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
Where
Beijing
Age
18 years and over
People
32
Run by
HC Biopharma Inc.
See details and how to joinNCT07306585
Phase 4Taking people
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Where
Wuhan
Age
18 years to 80 years
People
100
Run by
Tongji Hospital
See details and how to joinNCT07077486
Phase 1Taking people
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Where
Nanjing
Age
18 years to 65 years
People
21
Run by
Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07109986
Phase 2Taking people
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
Where
Nanjing
Age
18 years to 75 years
People
105
Run by
Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07363460
Phase 1Not yet taking people in China
KN5501 Cell Injection for Refractory SLE(CLEAR)
Where
Beijing, Bengbu, Luoyang, Nanjing, Shanghai, Wuhan
Age
18 years to 70 years
People
36
Run by
Ruitherapeutics Co., LTD
See details and how to joinNCT07358988
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087
No phaseTaking people
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
Where
Hangzhou
Age
5 years and over
People
6
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07352332
Early phase 1Taking people
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
Where
Wuhan
Age
18 years to 65 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07339332
Phase 1Taking people
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Where
Nanjing
Age
18 years and over
People
18
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07331467
No phaseNot yet taking people in China
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
Where
Wuhan
Age
18 years to 60 years
People
22
Run by
Tongji Hospital
See details and how to joinNCT07314567
No phaseTaking people
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Where
Hangzhou
Age
18 years to 65 years
People
15
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270